Search results
Texas Company's Mission to Cure Macular Degeneration Blindness
The Joplin Globe· 7 days agoTwenty Million people in America (12% of the population over 40) have Macular Degeneration and Two...
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 23 hours agodropped nearly 30% in premarket trading Monday after the company said its experimental...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 11 hours ago(NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet ...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 5 days agoThe paper-based KeepSight Journal from the International Macular and Retinal Foundation, Genentech's...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Benzinga via Yahoo Finance· 22 hours agoOn Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2...
A Revolution In Gene Therapy Is Unfolding, Bringing Hope for Vision Loss
Newswise· 4 days agoTwo treatments for retinal diseases, invented by Neena Haider, PhD, that currently are in clinical trials run by Ocugen, represent a conceptually broad, new approach that ...
...Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry...
Benzinga· 6 days agoLuxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI) in Rensselaer, New York, today announced receipt of a $4 million grant from the
Scientists find potential treatment target for leading cause of blindness
Investing.com· 5 days agoNew Delhi, May 2 (IANS) US scientists have found answers to why treatment for neovascular...
EyePoint reports mixed results in diabetic retinopathy trial By Investing.com
Investing.com· 18 hours agoEyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) announced interim results from its Phase 2...
EyePoint tumbles 30% premarket on failed Phase 2 study (NASDAQ:EYPT)
Seeking Alpha· 23 hours agoEyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase...